Get the Stockscreener App
7.30
10.54%
-0.86
Indaptus Therapeutics Inc stock is traded at $7.30, with a volume of 9,373.
It is down -10.54% in the last 24 hours and down -34.53% over the past month.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
See More
Previous Close:
$8.16
Open:
$8.1
24h Volume:
9,373
Relative Volume:
0.00
Market Cap:
$4.18M
Revenue:
-
Net Income/Loss:
$-15.42M
P/E Ratio:
-3.9674
EPS:
-1.84
Net Cash Flow:
$-13.41M
1W Performance:
-26.41%
1M Performance:
-34.53%
6M Performance:
+702.20%
1Y Performance:
+256.10%
1-Day Range:
$7.30
$8.17
1-Week Range:
$7.30
$10.57
52-Week Range:
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
7.30 | 4.67M | 0 | -15.42M | -13.41M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
Should I hold or sell Indaptus Therapeutics Inc. stock in 2025Chart Pattern Updates For Fast Growth - jammulinksnews.com
Is Indaptus Therapeutics Inc. stock a growth or value playForecast Model for Intraday Buy Signals - Newser
How to escape a deep drawdown in Indaptus Therapeutics Inc.Market Correction Proof Stock Screening Analysis - Newser
What makes Indaptus Therapeutics Inc. stock price move sharplyBuy Signal System Based on Price Action - Newser
Using data models to predict Indaptus Therapeutics Inc. stock movementFree Secure Return Focused Investment Plan - Newser
When is Indaptus Therapeutics Inc. stock expected to show significant growthStock Market Data Feed For Consistent Profits - jammulinksnews.com
Is Indaptus Therapeutics Inc. stock a good hedge against inflationLow Exposure Strategy with Sector Analysis - Newser
What is Indaptus Therapeutics Inc. company’s growth strategyAI Powered Growth Plan For 2025 - jammulinksnews.com
How Efficient Is Indaptus Therapeutics Inc. at Controlling Operating CostsConsistent Profit Signals with AI Models - Newser
Will Indaptus Therapeutics Inc. stock recover after recent dropFree Real Profit Trade Plan Suggestions - Newser
Using Bollinger Bands to evaluate Indaptus Therapeutics Inc.Multi-Year Signal Summary and Entry Timing - Newser
Why Indaptus Therapeutics Inc. stock attracts strong analyst attentionShort Term Setup With Predictive Chart Confirmed - beatles.ru
Is Indaptus Therapeutics Inc. in Accumulation Phase NowConsistent Profit Pattern Recognition Tools Shared - metal.it
Indaptus Therapeutics Secures Approval for Private Placement - TipRanks
Published on: 2025-07-29 21:05:39 - metal.it
How volatile are INDP's quarterly expenses? - AInvest
How many analysts rate Indaptus Therapeutics Inc. as a “Buy”Stock Strategy Entry Points Backed By Experts - jammulinksnews.com
Why is Indaptus Therapeutics Inc. stock attracting strong analyst attentionUnlock exclusive stock market forecasts - jammulinksnews.com
Does Indaptus Therapeutics Inc. stock perform well during market downturnsAchieve breakthrough profits with expert advice - jammulinksnews.com
How does Indaptus Therapeutics Inc. compare to its industry peersMassive portfolio appreciation - jammulinksnews.com
How strong is Indaptus Therapeutics Inc. company’s balance sheetFree Investment Case Studies - jammulinksnews.com
Published on: 2025-07-28 05:00:38 - jammulinksnews.com
What institutional investors are buying Indaptus Therapeutics Inc. stockAchieve impressive returns with smart timing - jammulinksnews.com
What are Indaptus Therapeutics Inc. company’s key revenue driversMaximize gains with expert trading strategies - jammulinksnews.com
How high can Indaptus Therapeutics Inc. stock price go in 2025High Reward Swing Trades - Newser
Indaptus Therapeutics Inc. Stock Support and Resistance Levels You Should KnowTrend Following Trades - Newser
What analysts say about Indaptus Therapeutics Inc. stockDynamic capital growth - PrintWeekIndia
Is Indaptus Therapeutics Inc. a good long term investmentConsistent triple returns - Autocar Professional
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):